Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma

Karun Neupane1 Department of Internal Medicine, Manipal College of Medical Sciences, Pokhara, Gandaki, NepalCorrespondence[email protected]

Ahsan Wahab2 Department of Internal Medicine, Baptist Medical Center South/University of Alabama at Birmingham, Montgomery, AL, USA

Adeel Masood3 Department of Internal Medicine, Tidal Health Peninsula Regional, Salisbury, MD, USA

Tehniat Faraz4 Department of Biochemistry, Dow University of Health Sciences, Karachi, Sindh, Pakistan

Saman Bahram5 Department of Internal Medicine, Dow University of Health Sciences, Karachi, Sindh, Pakistan

Hamid Ehsan6 Department of Biomedic Sciences/Biohazardous Threat Agents & Emerging Infectious Diseases, Georgetown University, Washington, DC, USA

Abdul Hannan7 Department of Hematology/Oncology, Simmons Cancer Institute at Southern Illinois University School of Medicine, Springfield, IL, USA

Faiz Anwer8 Department of Hematology/Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA

Your download is now in progress and you may close this window